Physician profile
Amy Goodpaster
NPI 1518639640
$3,728.35
in general payments reported to CMS, 2019-2025
31 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $609 · 2023: $854 · 2024: $1,037 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,985 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,985.28 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,023.98 | 2022-2025 | |
| Novo Nordisk INC | $802.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Alexion Pharmaceuticals, INC. | $264.62 | 2022-2025 | Strensiq |
| Axsome Therapeutics, INC. | $246.33 | 2024-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.67 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $129.91 | 2023-2025 | Mounjaro, Zepbound |
| Corcept Therapeutics | $123.19 | 2024-2025 | Korlym |
| Neos Therapeutics, LP | $97.12 | 2022-2025 | Adzenys Xr-Odt |
| Pfizer INC. | $95.82 | 2023-2025 | |
| Exact Sciences Corporation | $90.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ibsa Pharma INC. | $83.52 | 2021-2024 | Tirosint, Licart, Tirosint |
| Amneal Pharmaceuticals LLC | $79.93 | 2022-2024 | Unithroid |
| Amgen INC. | $65.49 | 2024-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $57.50 | 2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $43.66 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $38.80 | 2022-2023 | Trintellix |
| Esperion Therapeutics, INC. | $34.64 | 2025 | Nexletol |
| Paratek Pharmaceuticals, INC. | $28.44 | 2022 | |
| Fisher & Paykel Healthcare INC | $28.19 | 2025 | Fisher & Paykel Healthcare |
| Azurity Pharmaceuticals, INC. | $28.04 | 2023 | Adthyza |
| Astrazeneca Pharmaceuticals LP | $27.15 | 2024 | Farxiga |
| Acella Pharmaceuticals, LLC | $27.04 | 2023 | NP Thyroid 60 |
| Idorsia Pharmaceuticals US INC | $20.05 | 2023 | Quviviq |
| Hologic Sales and Service, LLC | $20.02 | 2024 | Aptima |
| Nestle Healthcare Nutrition INC. | $18.59 | 2022 | |
| Ironshore Pharmaceuticals INC. | $18.48 | 2021 | |
| Collegium Pharmaceutical, INC. | $15.95 | 2025 | Jornay Pm |
| Shield Therapeutics INC | $15.86 | 2023 | Accrufer |
| Supernus Pharmaceuticals, INC. | $15.01 | 2025 | Qelbree |
| Biohaven Pharmaceuticals, INC. | $14.94 | 2021 | |
| Biosense Webster, INC. | $14.42 | 2025 | Soundstar, Nuvision Ice Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Goodpaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.